All the latest recruitment news in Cardiff.
A biotech business that is pioneering a new approach to tackling the growing threat of antibiotic resistance – or superbugs – has chosen Cardiff Medicentre as its base.
Nemesis Bioscience Ltd (Cambridge, UK) has announced that it has raised £300,000 in seed funding from a consortium of Angel investors and from Finance Wales.
The company is using the funding to extend the application of its proprietary biological therapeutics – Nemesis Symbiotics© that inactivate antibiotic resistance. They have also opened a new therapeutic development facility in the Medicentre located at the University Hospital of Wales, Cardiff. The company will retain a research laboratory on the Babraham Research Campus, Cambridge.
Nemesis Bioscience was founded in 2014 by microbiologist Frank Massam and molecular biologists Conrad Lichtenstein and Gi Mikawa. Now that its innovation has been confirmed as having proven potential, the team is ready to begin the journey towards clinical trials and commercialisation.
The company’s concept is around halting the significant problem of bacteria becoming resistant to antibiotics. As this resistance develops, the danger is that antibiotics could eventually be of no use at all.
For more information visit the Nemesis Bioscience website.